Nuveen’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-47,553
| Closed | -$2.27M | – | 3298 |
|
|
2025
Q3 | $2.27M | Sell |
47,553
-24,103
| -34% | -$668K | ﹤0.01% | 2254 |
|
|
2025
Q2 | $1.15M | Sell |
71,656
-5,951
| -8% | -$96.4K | ﹤0.01% | 2542 |
|
|
2025
Q1 | $1.18M | Buy |
77,607
+1,362
| +2% | +$21.8K | ﹤0.01% | 2566 |
|
|
2024
Q4 | $1.55M | Buy |
76,245
+13,504
| +22% | +$340K | ﹤0.01% | 2493 |
|
|
2024
Q3 | $1.61M | Sell |
62,741
-17,104
| -21% | -$285K | ﹤0.01% | 2523 |
|
|
2024
Q2 | $1.03M | Buy |
+79,845
| New | +$1.28M | ﹤0.01% | 2720 |
|
|
2022
Q3 | – | Sell |
-6,152
| Closed | -$277K | – | 3294 |
|
|
2022
Q2 | $277K | Buy |
6,152
+2,000
| +48% | +$158K | ﹤0.01% | 3111 |
|
|
2022
Q1 | $340K | Hold |
4,152
| – | – | ﹤0.01% | 3099 |
|
|
2021
Q4 | $589K | Buy |
4,152
+1,827
| +79% | +$270K | ﹤0.01% | 3029 |
|
|
2021
Q3 | $328K | Buy |
2,325
+915
| +65% | +$125K | ﹤0.01% | 3238 |
|
|
2021
Q2 | $207K | Buy |
+1,410
| New | +$216K | ﹤0.01% | 3245 |
|
Nuveen's TRML Position: Q4 2025 in Review
Nuveen sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 47,553 shares — an estimated $2.27M sold.
Nuveen first reported a position in TRML in Q2 2021 and held it in 11 quarters. The position peaked at $2.27M in Q3 2025. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Nuveen reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Nuveen sold 47,553 Tourmaline Bio shares in Q4 2025, an estimated $2.27M.
- Nuveen first reported a position in Tourmaline Bio in Q2 2021 and held it in 11 quarters.
- Nuveen's Tourmaline Bio position peaked at $2.27M in Q3 2025.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Nuveen's 13F filing for Q4 2025, filed 12 Feb 2026.